Treatment of JAK2-Mutated Essential Thrombocythemia in a 64-Year-Old Without Prior Thrombosis
This 64-year-old patient with JAK2-mutated ET and no thrombosis history is classified as high-risk and requires cytoreductive therapy with hydroxyurea plus low-dose aspirin (81-100 mg daily). 1
Risk Stratification
Your patient falls into the high-risk category based on the revised IPSET-Thrombosis classification. The combination of age >60 years AND JAK2 mutation presence automatically designates high-risk status, even without prior thrombotic events 1. This is critical because:
- JAK2-mutated patients >60 years have significantly elevated thrombosis risk compared to JAK2-negative patients of the same age
- The presence of JAK2 mutation increases venous thrombosis risk (incidence rate ratio 4.0) 2
- High-risk patients have 50% thrombosis-free survival at only 7 years without adequate treatment 1
Treatment Algorithm
First-Line Therapy
Hydroxyurea is the cytoreductive drug of choice at any age for high-risk ET 3, 1. The treatment regimen should include:
- Hydroxyurea as first-line cytoreductive therapy
- Low-dose aspirin (81-100 mg daily) for thrombosis prevention 1
- Cardiovascular risk factor management (hypertension, diabetes, hyperlipidemia, smoking cessation) 1
Alternative First-Line Options
Pegylated interferon-α can be considered as an alternative first-line agent, particularly if:
- The patient is younger and concerned about long-term hydroxyurea exposure
- There are specific patient variables favoring interferon over hydroxyurea 1
However, given this patient's age (64 years), hydroxyurea remains the preferred initial choice based on the strongest guideline evidence 3.
Second-Line Therapy
Switch cytoreductive therapy if any of the following occur 1:
- Intolerance or resistance to hydroxyurea (see specific criteria in guidelines)
- New thrombosis despite treatment
- Acquired von Willebrand disease with major bleeding
- Symptomatic or progressive splenomegaly
- Progressive leukocytosis
- Vasomotor symptoms not responsive to aspirin
Anagrelide or interferons (if not previously used) are second-line options 1.
Critical Monitoring Points
Before Initiating Therapy
- Perform bone marrow biopsy to exclude disease progression to myelofibrosis 1
- Screen for acquired von Willebrand syndrome if platelet count >1000 × 10⁹/L, as this affects bleeding risk and aspirin decisions 1, 4
Ongoing Surveillance
Monitor for:
- New thrombotic or hemorrhagic events
- Disease-related symptoms (pruritus, night sweats, fatigue)
- Transformation to myelofibrosis (approximately 10% at 10 years) 2
- Leukemic transformation (<1% at 10 years) 2, 5
Common Pitfalls to Avoid
Do not withhold cytoreductive therapy based solely on platelet count. The decision is driven by risk category, not platelet level. High-risk patients require cytoreduction regardless of the degree of thrombocytosis 1.
Do not use aspirin alone without cytoreduction in this high-risk patient. The ELN guidelines explicitly state that high-risk ET requires cytoreductive therapy, not just antiplatelet therapy 3.
Caution with aspirin if extreme thrombocytosis (>1500 × 10⁹/L) is present, as acquired von Willebrand syndrome increases bleeding risk. In such cases, cytoreduction to lower platelet counts should precede or accompany aspirin initiation 1, 4.
Evidence Strength
The recommendation for cytoreductive therapy in high-risk ET is supported by:
- Level 1 evidence: A randomized trial of 114 high-risk ET patients showed hydroxyurea significantly reduced thrombotic events (3.6% vs 24%, P<0.01) 2
- Consensus guidelines: Both the 2011 ELN guidelines 3 and the more recent 2017 NCCN guidelines 1 consistently recommend cytoreduction for high-risk disease
- Recent validation: 2024-2025 expert reviews continue to support this approach 5, 6
The JAK2 mutation status specifically influences this decision because JAK2-mutated patients have higher thrombosis risk, making the age >60 threshold more clinically significant than in JAK2-negative patients 1.